Zobair Younossi and the Surfers, including Global NASH Council member Jörn Schattenberg, discuss Zobair’s work through the Global NASH Council and some implications for low SDI vs. high SDI countries.
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
This conversation focuses on ways the new MASLD Nomenclature can improve the ways providers explain MASH to patients.
This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group explores the goal of provider and patient liver education, key goals for liver awareness and the potential for direct-to-consumer advertising of GLP-1s for weight loss to garble the “liver awareness” message.
